Company intelligence / Profile preview

Jumpcode Genomics

San Diego, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Jumpcode Genomics has commercialized proprietary CRISPR-based sample depletion kits (CRISPRclean, DepleteX) that demonstrably improve sensitivity and reduce costs for NGS; these tools have enabled identification of novel signals in infectious disease, cancer, pharmacogenomics, and more

Therapeutic areas: ImmunologyMetabolic DisordersInfectious DiseasesRare DiseasesOtherOncology
Modalities: CRISPR-based technologyReagent kitsDevice (for genomic sample prep)
Industry: Molecular Diagnostics

Partnerships

UCSF (clinical research use case)Element Bio (Scientific Advisory Board partnership)Scripps (Scientific Advisory Board partnership)Lyzz Capital, Arboretum Ventures (investors/board involvement)

Beyond the preview

Go deeper on Jumpcode Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jumpcode Genomics.

Explore the full profile